PCI Biotech fourth quarter and preliminary full year 2021 results
February 18, 2022 01:00 ET
|
PCI Biotech Holding ASA
Oslo (Norway), 18 February 2022 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim Q4 and preliminary full-year 2021 results. Please find enclosed the...
PCI Biotech: Invitation to Q4 2021 result presentation
February 14, 2022 06:50 ET
|
PCI Biotech Holding ASA
Oslo, Norway, 14 February 2022 - PCI Biotech (OSE: PCIB) invites to a presentation of the company's Q4 and preliminary full-year 2021 results on Friday 18 February 2022 at Oslo Cancer Cluster...
PCI Biotech: Update on the RELEASE trial
January 24, 2022 15:00 ET
|
PCI Biotech Holding ASA
Oslo (Norway), 24 January 2022 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced that the company has decided to stop the RELEASE study and focus their drug...
PCI Biotech: Publication of preclinical tuberculosis results
January 11, 2022 03:01 ET
|
PCI Biotech Holding ASA
Oslo (Norway), 11 January 2022 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced that results from preclinical studies on tuberculosis performed in collaboration...
PCI Biotech and MDimune announce research collaboration agreement
January 05, 2022 01:00 ET
|
PCI Biotech Holding ASA
Oslo, Norway and Seoul, South Korea 5 January, 2022 – PCI Biotech (OSE: PCIB), a Norwegian cancer focused biopharmaceutical company and MDimune Inc. (“MDimune”), a private South Korean biotech company...
PCI Biotech to present at DNB Nordic Healthcare Conference 2021
December 14, 2021 05:45 ET
|
PCI Biotech Holding ASA
Oslo (Norway), 14 December 2021 – PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing innovative therapeutics that address significant unmet medical needs in cancer today announced...
PCI Biotech: Independent Data Monitoring Committee recommends continuation of two treatments in the RELEASE trial
December 13, 2021 11:12 ET
|
PCI Biotech Holding ASA
Oslo (Norway), 13 December 2021 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced that the Independent Data Monitoring Committee (IDMC) has reviewed the safety...
PCI Biotech: Update on regulatory interactions for the RELEASE trial
December 07, 2021 12:45 ET
|
PCI Biotech Holding ASA
Oslo (Norway), 7 December 2021 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced that the company has concluded on the interactions with regulatory authorities in...
PCI Biotech and Immunicum Announce an Extension to Their Research Collaboration to Explore Novel Cancer Vaccination Treatments
November 30, 2021 02:00 ET
|
PCI Biotech Holding ASA
Oslo, Norway, November 30, 2021 - PCI Biotech Holding ASA (OSE: PCIB), a cancer focused biopharmaceutical company with a unique intracellular delivery technology via Photochemical Internalisation and...
PCI Biotech to present at ABGSC Nordic Rare Disease Seminar
November 29, 2021 05:07 ET
|
PCI Biotech Holding ASA
Oslo (Norway), 29 November 2021 – PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing innovative therapeutics that address significant unmet medical needs in cancer today announced...